Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) recovered off lows big-time yesterday after the company announced an updated positive clinical data from its Phase 2 trial of Picoplatin in colorectal cancer and new Phase 1 cardiac safety trial results. Shares are continuing the recover this morning with a 10.9% gain to $2.71 on over 425,000 shares as of 8:26 AM EST. This is on the heels of a huge drop from $7.58 on Friday to $1.83 on Monday after a failure of a picoplatin study in lung cancer trials.
JON C. OGG
No comments:
Post a Comment